** Shares of genetic research equipment maker 10x Genomics TXG.O down 2.7% to $11.68 premarket

** Co sees 2025 revenue in the range of $610 million to $630 million, with midpoint below average of analyst's estimates of $622 million - LSEG data

** Posts Q4 loss of 40 cents per share compared to analyst's estimates of 29 cents per share

** "Despite the current uncertainty within U.S. academic research, we continue to have strong conviction in the large opportunity ahead" - CEO Serge Saxonov

** Brokerage Leerink Partners said on Monday that sales of companies such as TXG and Quanterix QTRX.O would be hit in Q1, as research centers and medical schools get cautious about purchasing equipment amid expected cost cuts of $4 billion at the National Institutes of Health

** In the last 12 months, TXG has fallen 74.3%

(Reporting by Siddhi Mahatole)

((siddhiprabhanjan.mahatole@thomsonreuters.com))